NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer - Seite 2

A comparison of the data from the ABC-08 and ABC-02 studies is provided in the following table:

Objective Response Rates in ABC-08 and ABC-02
	ABC-08	ABC-021
	NUC-1031 + cisplatin 625 mg/m2 + 25 mg/m2	gemcitabine + cisplatin 1000 mg/m2 + 25 mg/m2
Complete Response	13% (1/8)	0.6% (1/161)
Partial Response	38% (3/8)	25.5% (41/161)
Objective Response Rate	50% (4/8)	26.1% (42/161)

1. Valle et al. N Engl J Med 2010; 363:1273-1281

Hugh S. Griffith, NuCana's Chief Executive Officer, said: "We are excited by the exceptional results achieved so early in this study.  Consistent with our strategy of rapidly advancing our new medicines in multiple cancer types, and based on the results of this study, we plan to initiate a pivotal study of Acelarin and cisplatin in front-line advanced biliary tract cancer in 2018."

About NuCana plc

NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide(TM) technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Our most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies for patients with ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumors.